1 TRM/MDT ‐ all studies |
14 |
2555 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.93, 1.79] |
1.1 TRM |
3 |
807 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.05 [0.74, 12.64] |
1.2 MDT |
9 |
1427 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.20 [0.84, 1.70] |
1.3 Others |
2 |
321 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.38 [0.45, 4.21] |
2 TRM/MDT ‐ different high‐dose settings |
14 |
2555 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.93, 1.79] |
2.1 High‐dose sequential therapy without induction |
2 |
224 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.40, 4.04] |
2.2 Abbreviated standard induction therapy |
8 |
1569 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.27 [0.88, 1.83] |
2.3 Full standard induction therapy |
4 |
762 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.45 [0.57, 3.67] |
3 TRM/MDT ‐ patients' status at randomisation |
14 |
2555 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.93, 1.79] |
3.1 Patients irrespectively of disease status |
11 |
1896 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.25 [0.89, 1.74] |
3.2 Patients in CR or PR |
3 |
659 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.07 [0.49, 19.20] |
4 TRM/MDT ‐ methodological quality |
14 |
2555 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.93, 1.79] |
4.1 Sufficient method |
12 |
2234 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.91, 1.81] |
4.2 Insufficient or unknown method |
2 |
321 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.38 [0.45, 4.21] |
5 TRM/MDT ‐ study size |
13 |
2014 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.92, 1.78] |
5.1 >100 pts. |
8 |
1696 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.33 [0.89, 1.99] |
5.2 <100 pts. |
5 |
318 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.16 [0.66, 2.05] |
6 TRM/MDT ‐ protocol adherence to HDT |
12 |
1791 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.91, 1.79] |
6.1 >70% |
7 |
1033 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.58, 1.70] |
6.2 <70% |
5 |
758 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.53 [0.99, 2.34] |
7 TRM/MDT ‐ preparative HDT regimen |
13 |
2014 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.92, 1.78] |
7.1 BEAC |
3 |
393 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.48 [0.49, 12.58] |
7.2 BEAM |
6 |
1280 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.80, 1.66] |
7.3 TBI |
3 |
215 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.02 [0.75, 5.43] |
7.4 Others |
1 |
126 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.1 [0.16, 7.57] |
8 TRM/MDT ‐ bone marrow involvement |
12 |
1791 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.91, 1.79] |
8.1 >20% of pts. |
5 |
891 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.05 [0.58, 1.89] |
8.2 <20% of pts. |
7 |
900 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.42 [0.94, 2.13] |
9 TRM/MDT ‐ % of patients with DLCL (wide def.) |
12 |
1791 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.91, 1.79] |
9.1 >80% |
8 |
1008 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.42 [0.96, 2.10] |
9.2 <80% |
4 |
783 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.50, 1.89] |
10 TRM/MDT ‐ % of patients with DLCL (narrow def.) |
12 |
1791 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.28 [0.91, 1.79] |
10.1 >70% |
6 |
673 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.24 [0.73, 2.10] |
10.2 <70% |
6 |
1118 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [0.84, 2.01] |